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Abstract
Present investigation was aimed at formulation, characterization and evaluation of 
phytosomal complex tablets for sustained delivery of Phyllanthus amarus complex. 
Phyllanthin, one of the active lignin present in this plant species was isolated from 
the aerial parts, by silica gel column chromatography employing gradient elution 
with hexane–ethyl acetate solvent mixture. It was obtained in high yields (1.23%), 
compared to reported procedures and the purity was ascertained by HPTLC analysis. 
Phyllanthin was characterized for M.P, UV–Visible spectrophotometry, FT-IR, 1H 
NMR, 13C and NMR analysis. Release kinetics was evaluated by using United States 
Pharmacopeia (USP)-22 type I dissolution apparatus. Scanning electron microscopy 
was used to visualize the effect of dissolution medium on matrix tablet surface. 
HPTLC was carried out for quantitative and qualitative estimation of Phyllanthin in 
Phyllanthus amarus and R
f 
of phyllanthin was found to be about 0.25. The content 
was found to be maximum for phytosomal complex of phyllanthus formed by vaccum 
drying of 1:1 drug excipient ratio. The in-vitro drug release study revealed that 
optimized formulation sustained the drug release for 12 hr (88.1% ± 4.1% release). 
Fitting the in vitro drug release data to Korsmeyer equation indicated that diffusion 
along with erosion could be the mechanism of drug release.
Key words: - Phyllanthus amarus, tablet formulation, in vitro release 
1 INTRODUCTION
According to the World Health Organization about 80% of the population in many third world countries still uses traditional medicine (e.g., medicinal plants) for their primary health care, due to poverty and lack 
of access to modern medicine. Since about 80 % of the 6.1 billion people of 
the world live in less developed countries i,e 3.9 billion people will likely use 
medicinal plants on a frequent basis. The investigation of plants as potential 
sources of new drugs to treat cancer, AIDS and malaria requires the search of as 
many resources as possible. The discovery of phytochemical compounds with, 
for example, cytotoxic and anti-tumor activity could lead to the production of 
new drugs for the treatment of cancer (De Silva., 1997).
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Herbal medicines continue to be a popular healthcare choice with the general 
public not only for health maintenance and wellbeing, minor ailments (e.g. 
coughs and colds), chronic conditions (e.g. back pain) and serious chronic 
diseases (e.g. asthma, cancer, depression, diabetes), but also for ‘enhancement’ 
of functions or processes, such as the use of Ginkgo biloba products for 
memory enhancement. In an attempt to support the traditional use of herbal 
drugs with scientific evidences, lot of research has been carried out during past 
decades for establishing the pharmacological basis of action and clinical use 
of herbal medicines. On the other side, similar progress has been done in the 
field of phytochemistry for establishing the extraction procedure, purification/
isolation procedure and chemical structure of active constituents of these 
herbal medicines. As a net result we are shifting towards “purer forms of herbal 
drugs (Purified and standardised extracts, single phytoconstituent)” from the 
“crude” ones (i.e. roots, leaves etc.). The active ingredients of most of the 
biological plants are polar in nature even then the water solubility of most of 
the phytoconstituents is not very good as also the bioavailability. This can be 
either because of complex molecular nature and size of the phytoconstituents 
that causes the poor bioavailabilty (Dubey et.al.,2007).
Phytosome technology has been effectively used to enhance the 
bioavailability of many popular herbal extracts including milk thistle, ginkgo 
biloba, grape seed, green tea, hawthorn, ginseng etc and can be utilized 
for various therapeutic uses or for administration of dietary supplements. 
Phyllanthus amarus has also been shown to work as an antifungal, antibacterial 
and antiviral agent and reportedly is also used in traditional medicines in India 
to treat liver diseases, asthma and bronchial infections (Foo et.al., 1992). P. 
amarus is also used traditionally in India to treat cardiovascular problems 
(Chevallier., 2000). This popular medicinal herb is also a remedy around the 
world for influenza, dropsy, diabetes and jaundice (Foo, 1993). 
To examine the various advantages of phytosomes, especially their ability 
to enhance the bioavailability of hydrophilic phytoconstituents, as well as 
lipophilic phytoconstituents various therapeutic applications of phytosomes 
have been explored. Phytosomes are formulated by patented processes in 
which the standardized extract (having a standardized content of active 
principles) or active ingredients of herbs (like flavolignans and terpenoids) are 
bound to the phospholipids like phosphatidylcholine (PC) through a polar end. 
The phytosome technology produces small cells which protect the valuable 
components of the herbal extract from destruction by digestive secretions and 
gut bacteria. (Dubey et.al, 2007). Phytosomes are novel complexes which are 
prepared by reacting 2-3 moles, or preferably one mole of a natural or synthetic 
phospholipid, such as phosphatidylcholine, phosphatidylethanolamine or 
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phosphatidyiserine with one mole of phytoconstituent component, either 
alone or in the natural mixture, in aprotic solvent such as dioxane or acetone.
(Bombardelli et.al.,1993). From this, phytosomal complex can be isolated 
by precipitation with non-polar solvent such as aliphatic hydrocarbons or 
lyophilization or by spray drying.(Mascarella., 1991). In the complex formation 
of phytosomes, the ratio between these two moieties is in the range from 0.5-
2.0 moles (Jose et.al.,1987).
Therefore present investigation was aimed at formulation, characterization 
and evaluation of phytosomal complex tablets for sustained delivery of 
Phyllanthus amarus phytosomal complex.
2. MATeRIAl AND MeThOD 
2.1 Materials 
Standardized extract of Phyllanthus amarus was procured as gift sample 
from natural Remedies Pvt. Limited, Bangalore and Phospholipon 85G from 
Lipoid, Switzerland. All other materials and chemicals used were of either 
pharmaceutical or analytical grade.
2.2 Authentication
2.2.1 Nuclear magnetic resonance (NMR) 
The NMR (Bruker) spectrum of Phyllanthin was recorded using 
tetramethylsilane as internal standard 
2.2.2 High Performance Thin Layer Chromatography (HPTLC)
Chromatography was performed using commercially-prepared, Precoated 
silica gel HPTLC plates (20 × 20 cm, GF
254
 Merck, Germany). A Linomat V 
(Camag, Muttenz, Switzerland) automatic TLC applicator was used to apply 
samples and standards onto the TLC plate under a flow of nitrogen gas with 
dosage speed 200 nL/s. The samples were applied as 6 mm wide bands at 12 mm 
from the bottom and 15 mm from both sides. The syringe used was Hamilton 
micro liter (100µL) syringe. Each TLC plate was developed to a height of 
about 10 cm with a mobile phase of hexane: acetone: ethyl acetate (74:12:8) 
under laboratory conditions (25– 30°C and 40–50% relative humidity). Stock 
solution was prepared in methanol (1 mg/mL). Working solutions of standard 
were prepared by appropriate dilutions of the stock solution with methanol in 
concentration range of 800ng/ml, 1000ng/ml, 1200ng/ml, 1400ng/ml, 1600ng/
ml, 1800ng/ml and these concentrations were used to prepare calibration curve 
for HPTLC. 
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2.3 Preparation and evaluation of phytosomal 
complex
Phytosomes were formulated by Indena’s patented processes (www.indena.
com). Complex was prepared with standardized extract of Phyllanthus 
amarus and phospholipon 85 G at a molar ratio of 1:1 and 1:2. Weighed 
amount of standardized extract of Phyllanthus amarus and phospholipon 85 
G were taken in a 100 ml round bottom flask and 20 ml of dichloromethane 
was added. The mixture was refluxed at a temperature not exceeding 
40°C for 2 h. The resultant clear solution was evaporated and 10 ml of 
n-hexane was added to it with continuous stirring. One of the batch of drug–
phospholipid complex was precipitated and the precipitate was filtered and 
dried under vacuum to remove traces of solvents and the other batch was 
subjected to rota evaporation resulting in a thin film formation. This thin 
film was separated. The resultant drug–phospholipid complexes were kept 
in an amber colored glass bottle, flushed with nitrogen and stored at room 
temperature. 
2.3.1 Microscopic view of the complex 
Olympus (CH 20i) microscope was used for microscopic characterization 
of the complex. The complex was suspended in distilled water and a drop 
was placed on a slide and covered with a cover slip. Microscopic view of the 
complex was observed at a magnification of 400X. 
2.3.2 Scanning Electron Microscopy (SEM)
 The surface morphology of complex was investigated by Scanning Electron 
Microscope Model JSM6100 (Jeol). 
2.3.3 Fourier Transform Infrared Spectroscopy (FTIR) 
Fourier transform infrared spectrum (FTIR) was recorded for fractions using 
infrared spectrophotometer. Samples were prepared in KBr disk (2 mg sample 
/ 200 mg KBr) with a hydrostatic press at a force of 275790.292 Pascal’s for 
4 min. 
2.3.4 Determination of phyllanthin content in complex
The content of phyllanthin in phytosomal complex was determined by 
solubilizing 10mg/ml of complex in methanol and a 1µl aliquot of the resulting 
solution was injected into a HPTLC system using precoated silica gel HPTLC 
plates (20 × 20 cm, GF
254
 Merck, Germany) as stationary phase. The mobile 
phase was a mixture of hexane: acetone: ethyl acetate (74:12:8). Eluent was 
monitored at 220 nm. 
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2.4 Formulation of phytosomal complex tablets
2.4.1 Formation of granules
Tablets of Phyllanthin amarus were prepared by dry granulation technique 
using different polymers. Accurately weighed quantities of presieved drug and 
granulation materials [diluents (DCP) about 4%, phytosomal complex about 
50%, binder (MCC) 10% and glidant (Magnesium Stearate) 2%] were mixed 
& slugs were prepared. Blend was then subjected to Dry granulation, using flat 
faced punch.
Various parameters optimized were as follows: (Brook and Marsha, 1968).
   (I) Bulk Density (Db) 
   (II) Tapped Density (Dt)
 (III) Angle of Repose Carr’s Index 
 (IV) hausner Ratio (h)
Dry granulation method 
The slugs prepared were milled and passed through scree of 10 mesh size 
aperture. The granules were sieved. The final granules were blended and 
compressed using round flat punches tablet press (Multi Punch type, AK 
Industries, Nakodar, Punjab). Six batches of tablets were prepared for each 
formulation.
2.4.2 In vitro evaluation of tablets (Indian Pharmacopoeia., 1996)
Thickness 
The thickness of the tablets was measured by vernire caliper and expressed in 
mm. 
hardness
The hardness of the tablet was determined using a Monsanto hardness tester 
(Interlabs, Ambala, India) and expressed in Kg / cm2 .
Tensile Strength
The load (P) required to cause diametral fracture in a tablet was determined 
using the Monsanto hardness tester (Interlabs, Ambala, India). Ten tablets 
randomly selected from a given size fractions were used for the determination. 
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Where, t and D represent the thickness and diameter of the tablet respectively. 
Triplicate determinations were carried out for the various size fractions and 
mean determinations. 
Friability (F) (James Sworbrick et.al)
The friability of the tablet was determined using Roche Friabilator (model 
no 902). It is expressed in percentage (%). 10 tablets were initially weighed 
(W
initial
) and transferred into the friabilator. The friabilator was operated at 25 
rpm for four mins. The tablets were weighed again (W
final
). The percentage 









It is reported in Table 6.
Weight Variation 
Ten tablets were selected randomly from the lot and weighed individually 
to check for weight variation. IP limit for weight variation in case of tablets 
weighing upto 200mg is ± 7.5%.
In Vitro Disintegration Time
Water was used as disintegration medium. The apparatus was operated for 
15 mins with discs after which the state of tablets was examined. If the tablet 
failed to comply because of adherence to the discs, the test was repeated further 
with 6 tablets omitting the discs. 
In-vitro dissolution studies
In vitro dissolution studies for all the prepared tablets was carried out using 
USP paddle dissolution apparatus (model no DS 3000) at 50rpm in 500ml of 
phosphate buffer pH 6.8 as dissolution media, maintained at 37±0.5ºC. 5ml 
aliquots were withdrawn at the specified time intervals for 12 hr, filtered through 
whatman filter paper and assayed spectrophotometrically at 220nm. An equal 
volume of fresh medium, which was pre-warmed at 37±0.5 º C, was replaced 
into the dissolution media after each sampling to maintain the constant volume 
thought the test. The same procedure was repeated for F1,F2,F3,F4,F5,F6.
Scanning electron Microscopy (SeM)
After 12 hr of dissolution study optimized formulation F4 tablet was allowed 
to swell for 2 hr in PSB (pH 6.8). Tablet was than dried in desiccator and 
observed for any alteration in surface morphology using Scanning Electron 
Microscope Model (JSM6100 Jeol). 
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Stability studies
Stability studies were carried out for two months on the optimized formulation 
of sustained release phytosomal tablets. For stability study thirty tablets of 
optimized formulation were placed in humidity chamber (Sonar) at 75% RH, 
45°C. After two months, the optimized formulation was evaluated for weight 
variation, hardness, friability, disintegration and percentage drug content.
3 ReSUlTS AND DISCUSSION 
3.1 Spectroscopic data for P. amarus extract
3.1.1 NMR Spectroscopic Data for Phyllanthus amarus extract.
The 1H-NMR data of the Phyllanthus amarus was represented by distinctive 
aromatic hydrogen region [H-Ar: δ 6.72 – 6.53 (m)]; methylenedioxy moieties 
[O-CH
2
-O: δ 5.85 (s)]; methoxyl groups bonded to the aromatic ring (OMe-
Ar: δ 3.81 – 3.73, 3.51); methoxyl groups bonded to the alkyl moieties (OMe-
alkyl: δ 3.31 – 3.19); methynic groups [CH: δ 2.00 – 1.94 (m)]; methylenic 
groups [CH
2
: δ 3.00 – 2.54, 2.26 (m)]; The observed 1H-NMR and 13C-NMR 
of phyllanthin were reported as in Figure 1.
Figure 1: NMR spectra of phyllanthin
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Figure 2: Figure 5.5.HPTLC chromatogram of pure Phyllanthin
1h NMR (500 Mhz, CDCl
3
, TMS):
δ 6.75 [2H-5(5’),d, J = 8.0], 6.65 [2H-6(6’), dd, J = 8.0, 1.9], 6.60 [2H-2(2’), 
d, J = 1.9], 3.83 [6H-4(4’)-OCH
3
, s], 3.78 [6H-3(3’)-OCH
3
, s], 3.30 [6H-
9(9’)-OCH
3




δ: 133.75 (C-1, C-1’), 112.27 (C-2, C-2’), 148.85 (C-3, C-3’), 
 147.08 (C-4, C-4’), 111.07 (C-5, C-5’), 121.25 (C-6, C-6’), 35.11 (C-7, 




3.1.2 High performance thin layer chromatography of Phyllanthus 
amarus extract
HPTLC was carried out for quantitative and qualitative estimation of 
Phyllanthin in Phyllanthus amarus and R
f 
of phyllanthin was found to be about 
0.25 and found to be in accordance with results as reported and as shown in the 
chromatogram Figure 2.
3.1.3 Preparation of Calibration curve by HPTLC
HPTLC was carried out using various concentrations of Phyllanthin stated in 
the Table 1, and a calibration plot was prepared plotting concentration vs. area 
under curve as shown in Figure 3 
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y = 3.7319x + 327.93





















y = 3.7319x + 327.93
R2 = 0.9852
Figure 3: Calibration curve of phyllanthin by HPTLC
3.2 Preparation of Phytosomal Complex
The prepared complex was subjected for further evaluation parameters such as 
scanning electron microscopy, high performance thin layer chromatography, 
fourier transform infrared spectroscopy. Phyllanthus–phospholipid complex 
with different molar ratio 1:1 and 1:2 were analysed for content and surface 
morphology as shown in Table 2 and Figure 5. 
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Table 2: Content estimation of phyllanthin in phytosomal 
complex
Sr. no. Extract % of phyllanthin
1 Standardized extract 0.67
2 Phyllanthus 1:1(Vaccum) 2.8
3 Phyllanthus 1:2(Vaccum) 1.1
4 Phyllanthus 1:1(Rota) 1.2
5 Phyllanthus 1:2(Rota) 1.5
Figure 4: Microscopic view of phytosomal complex at 400X magnification.
Results showed that complex with molar ratio 1:1 showed more content (2.8%) 
in comparison to 1.2% in 1:2 and morphology was more even and spherical 
in 1:1 molar ratio. Therefore 1:1 was selected as optimized ratio for further 
evaluation.
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3.2.1 Microscopic view
Optical microscopy was used for the surface morphology of phytosomal 
complex. The microscopic view, as shown in figure 4 indicated the presence 
of spherical structures of the complex. The vesicles consisted of Phosphotidyl 
choline 85G and phytosomal complex were intercalated in the lipid layer as 
shown in Figure 4.
3.2.2 Determination of Phyllanthin Content in Complex
Content of Phyllanthin in the phytosomal complex was determined by 
HPTLC, by the HPTLC method as described in section below.The content 
is estimated by HPTLC method by different methods such as vaccum drying 
and rota evaporation in different ratios such as 1:1 and 1:2. The content was 
found to be maximum for phyllanthus formed by vaccum drying of 1:1 as 
shown in Table 2. Thus it was taken as optimized formulation for further 
evaluation.
3.3.3 Scanning Electron Microscopy (SEM)
The surface morphology of phospholipids and phytosomal complex as examined 
by SEM is Figure 5. Phytosomal complex was made up of phospholipids and 
drugs and appeared irregular spheres shape.
3.3.4 Fourier Transform Infrared Spectroscopy (FTIR)
During Fourier Transform Infrared Spectroscopy (FTIR) studies the intensity 
of the peak was modified but actually shift in the peak was negligible. So it 
can be concluded that the drug interaction between phytosomal excipient and 
phytosomal complex was negligible as shown in Figure 6.
Figure 5: SEM of phytosomal complex of ratio 1:1 (left) 1:2 (right)














3500 3000 2500 2000 1500 1000
Wavenumber cm-1
Figure 6: FTIR spectra of phytosomal complex









F1 80 100 - 1
F2 70 100 20 2
F3 80 100 10 2
F4 80 100 20 2
F5 80 120 20 2
F6 80 80 20 2
3. 4 Formation of granules
Six batches of granules (F1-F6) were prepared by process of dry granulation 
with different composition of polymers as shown in Table 3. 
The prepared granules were then subjected to various evaluation 
parameters such as bulk density, tapped density, angle of repose, Carr’s index, 
Hausner’s ratio. The results obtained for the different evaluation parameters 
were summarized in Table 4.
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Table 4: Various Characteristic parameter of different formulations
S.No Formulation 
Code








1 F1 0.352 ±0.0006 0.431 ±0.003 32.5 ±0.252 11.2 ±1.907 1.227±0.008
2 F2 0.363 ±0.0013 0.437 ±0.005 35.5 ±0.321 16.8 ±0.964 1.202±0.014
3 F3 0.358 ±0.0006 0.448 ±0.005 37.4 ±0.153 20.1 ±0.870 1.251±0.014
4 F4 0.351 ±0.004 0.392 ±0.008 29.5 ±0.252 10.4 ±0.316 1.126±0.024
5 F5 0.362 ±0.0012 0.424 ±0.011 33.5 ±0.306 14.5 ±2.339 1.170±0.032
6 F6 0.359 ±0.0008 0.401 ±0.002 32.5 ±0.252 18.5 ±0.530 1.116±0.004









1 F1 0.521 ±0.003 3.833 ±0.321 6.881 ±0.456 12.637 ±1.982
2 F2 0.520 ±0.005 4.200 ±0.265 6.025 ±0.330 28.650 ±1.660
3 F3 0.520 ±0.001 4.133 ±0.306 5.929 ±0.427 18.487 ±2.667
4 F4 0.510 ±0.003 6.233 ±0.899 9.129 ±0.432 5.263 ±0.934
5 F5 0.511 ±0.003 5.200 ±0.400 7.593 ±0.568 9.427 ±1.602
6 F6 0.517 ±0.004 5.300 ±0.200 7.622 ±0.252 24.390 ±1.480
3.4.1 Preparation of tablets
Six different batches with different composition were prepared by dry granulation 
process as show in table 4. The tablet thickness, hardness, tensile strength, 
disintegration time were determined the results are summarized in Table 5.
3.4.2 Evaluation parameters of different tablet formulations
When dissolution drug release was plotted into zero order, first order, Higuchi 
model it was found that optimized formulation F4 was best fitted into zero 
order model.
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For F1 formulation % cumulative release during 1st hour is 34.09% and 12th 
hour is 110.59%
For F2 formulation % cumulative release during 1st hour is 33.41% and 12th 
hour is 111.26%
For F3 formulation % cumulative release during 1st hour is 32.29% and 12th 
hour is 111.94%
For F4 formulation % cumulative release during 1st hour is 39.71% and 12th 
hour is 112.28%
For F5 formulation % cumulative release during 1st hour is 38.03% and 12th 
hour is 110.70% and. For F6 formulation % cumulative release during 1st 
hour is 37.13% and 12th hour is 109.01%
Because the graphs show cumulative drug release, the errors involved in the 
drug analysis are also cumulative. Therefore, the mean values showing more 
than 100% drug release reflect these cumulative errors in drug analysis. Further 
in the case of F4 optimized formulation release was prolonged to 12 hr hence 
the proposed phytosomal complex tablet can act as sustained release dosage 
form. Based upon the results the study can be further subjected for in vivo 
evaluation to explain its therapeutic potential.
3.4.3 Kinetic analysis of dissolution data
The kinetics of drug release of Phyllanthus amarus was determined by 
Higuchi’s model, zero order and first order kinetics as shown in Table 6. The 
different formulation followed Zero order as their r2 values were between 0.990 
to 0.998. 
Table 6:  Regression coefficient (r2) values of drug release data obtained from 




Zero order First Order higuchi Model
r2 r2 r2
F1 0.992 0.973 0.954
F2 0.995 0.968 0.977
F3 0.991 0.912 0.981
F4 0.998 0.967 0.973
F5 0.988 0.955 0.979
F6 0.990 0.973 0.964
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3.4.4 Scanning electron microscopy
Scanning electron microscopy (SEM) provides a qualitative assessment of size, 
shape, morphology, porosity, size distribution, crystal form, and consistency 
of powders or compressed dosage forms (Figure 5). This information can 
be correlated to assess dissolution behavior, bioavailability, and crystalline 
structure. SEM images also help analysts determine whether particles are 
maintaining desired physical characteristics during processing, including after 
compaction or direct compression. The surface morphology of phytosomal 
tablet after 0 hr and 12 hr as examined by SEM as in Figure 8. 
It is reported in the literature that more than 30% release of drug in the first 
hour of dissolution indicates the chance of dose dumping.
3.4.5 Stability studies
The observed results of stability studies on optimized formulations after two 
months are given in Tables 7 & 8. 
Table 8:  Cumulative percentage of drug release from optimized 
formulation at 75% RH, 45 °C after two months.






Table 7:   Evaluation parameters of optimized formulation, at 75%, 45°C RH, 
for two months.
Parameter Observation
At 0 day After two months
Weight variation (mg) n=5 910±4.25 910±3.76
Hardness (kg/cm2) n = 5 4.78±0.32 4.78±0.28
Friability (%) n = 5 0.06 0.469
Drug content (%) n = 5 2.46 2.30































0 100 200 300 400 500 600 700 800
Time (min)
F1 F2 F3 F4 F5 F6
Figure 7: In Vitro Dissolution data of different formulations
Figure 8: Scanning electron micrographs of tablet at 0hr (left) 12th hr (right)
4 CONClUSION 
HPTLC was carried out for quantitative and qualitative estimation of 
Phyllanthin in Phyllanthus amarus and R
f 
of phyllanthin was found to be about 
0.25. The phytosomal complex was prepared consisting of standardised extract 
and phospholipid. The microscopic study indicated the presence of spherical 
structures of the complex. The vesicles consisted of Phosphotidyl choline 85G 
and phytosomal complex were intercalated in the lipid layer. The content is 
estimated by HPTLC method by different methods such as vaccum drying and 
rota evaporation in different ratios such as 1:1 and 1:2. The content was found 
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to be maximum for phyllanthus formed by vaccum drying of 1:1.The surface 
morphology of physical mixture of phytosomal complex as examined by SEM. 
Phytosomal complex was made up of phospholipids and drugs and appeared 
irregular spheres shape. Fourier Transform Infrared Spectroscopy (FTIR) 
studies shows that the intensity of the peak was modified but actually shift in 
the peak was negligible. The physical mixture gives confirmation about their 
purity and showed no interaction between phytosomal complex and polymers 
used in the formulations. Phytosomal tablets of phytosomes were successfully 
formulated by dry granulation method with incorporation of polymers such as 
DCP, Avicel, Magnesium stearate in combination. DCP was used as a diluent 
and Avicel as a binder, magnesium stearate as glidant.
The Phytosomal matrix tablet possessed the required physicochemical 
evaluation such as tablet thickness, hardness, tensile strength, disintegration 
time weight variation, friability and drug content. The drug content of the 
prepared formulation was within the acceptable range. The formulation F4 
showed maximum drug content.
Scanning electron microscopy (SEM) study was performed on the optimized 
batch (F4) of phytosomal tablet showed the surface morphology of phytosomal 
tablet after 0hr and 12hr by SEM studies. It is reported in the literature that 
more than 30% release of drug in the first hour of dissolution indicates the 
chance of dose dumping. Among the various formulation batches, F4 showed 
the maximum drug release at the end of 12hr. The optimized formulation (F4) 
showed maximum drug release at the end of 1st hour (39.71%) and at the end 
of 12th hour (112.28%). It was observed that all the formulations were best 
fitted to zero order and Higuchi model. The stability studies indicated that 
no change in physical appearance was noticed upon visual inspection of the 
tablets. All the formulations showed more than 90% of drug content during 
both accelerated and room temperature storage conditions.
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